Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:667-677, doi:10.1016/j.jacc.2008.10.047
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santilli, F.
Right arrow Articles by Patrono, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santilli, F.
Right arrow Articles by Patrono, C.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: ANTIPLATELET THERAPY

Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays

Implications for Aspirin "Resistance"

Francesca Santilli, MD*, Bianca Rocca, MD, PhD{dagger}, Raimondo De Cristofaro, MD{ddagger}, Stefano Lattanzio, BSc*, Laura Pietrangelo, BSc*, Aida Habib, PhD§, Caterina Pettinella, PhD*, Antonio Recchiuti, PhD*, Elisabetta Ferrante, BSc*, Giovanni Ciabattoni, MD*, Giovanni Davì, MD* and Carlo Patrono, MD{dagger},*

* Center of Excellence on Aging, "G. d'Annunzio" University Foundation, Chieti, Italy
{dagger} Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
{ddagger} Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
§ American University of Beirut, Beirut, Lebanon

Manuscript received July 25, 2008; revised manuscript received October 8, 2008, accepted October 14, 2008.

* Reprint requests and correspondence: Prof. Carlo Patrono, Department of Pharmacology, Catholic University School of Medicine, Largo F. Vito 1 00168 Rome, Italy (Email: carlo.patrono{at}rm.unicatt.it).

Objective: This study was conducted to assess the thromboxane (TX) dependence of biochemical and functional indexes used to monitor the effect of low-dose aspirin.

Background: Functional assays of the antiplatelet effects of low-dose aspirin variably reflect the TX-dependent component of platelet aggregation. Previous studies of aspirin resistance were typically based on a single determination of platelet aggregation.

Methods: We assessed the TXB2 dependence of biochemical and functional indexes, as well as their intersubject and intrasubject variability during administration of the drug and after its withdrawal in 48 healthy volunteers randomized to receive aspirin 100 mg daily for 1 to 8 weeks.

Results: Serum TXB2 was uniformly suppressed by 99% of baseline. Urinary 11-dehydro-TXB2, arachidonic acid-induced aggregation, and VerifyNow Aspirin (Accumetrics Inc., San Diego, California) showed stable, incomplete inhibition (65%, 80%, and 35%, respectively). Adenosine diphosphate- and collagen-induced aggregation was highly variable and poorly affected by aspirin, with an apparent time-dependent reversal. Inhibition of platelet cyclooxygenase activity was nonlinearly related to inhibition of platelet aggregation. Platelet function largely recovered by day 3 post-aspirin, independently of treatment duration. With any functional assay, occasionally "resistant" subjects were found to be "responders" on previous or subsequent determinations.

Conclusions: Platelet cyclooxygenase activity, as reflected by serum TXB2 levels, is uniformly and persistently suppressed by low-dose aspirin in healthy subjects. However, the effect of aspirin is variably detected by functional assays, potentially leading to misclassification of "responder" as "resistant" phenotypes owing to poor reproducibility of functional measurements. The nonlinearity of the relationship between inhibition of TX production and inhibition of platelet function has important clinical implications.

Key Words: aspirin • platelets • prostaglandins • antiplatelet drugs • pharmacology

Abbreviations and Acronyms
  AA = arachidonic acid
  ADP = adenosine diphosphate
  COX = cyclooxygenase
  CV = coefficient of variation
  NSAID = nonsteroidal anti-inflammatory drug
  Tmax = maximal aggregation
  TX = thromboxane


Related Articles

Aspirin Resistance: Transient Laboratory Finding or Important Clinical Entity?
Eli I. Lev
J. Am. Coll. Cardiol. 2009 53: 678-680. [Full Text] [PDF]

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A21-A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, et al.
Antiplatelet agents for the treatment and prevention of atherothrombosis
Eur. Heart J., December 1, 2011; 32(23): 2922 - 2932.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. W. Eikelboom and G. J. Hankey
Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Cause of Aspirin Resistance?
J. Am. Coll. Cardiol., August 9, 2011; 58(7): 762 - 764.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. F. Storey
Exploring Mechanisms of Graft Occlusion: Toward Improved Outcomes in Coronary Artery Bypass Graft Surgery
J. Am. Coll. Cardiol., March 1, 2011; 57(9): 1078 - 1080.
[Full Text] [PDF]


Home page
haematolHome page
G. Renda, M. Zurro, G. Malatesta, B. Ruggieri, and R. De Caterina
Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance
Haematologica, December 1, 2010; 95(12): 2095 - 2101.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
L. Brass
Understanding and Evaluating Platelet Function
Hematology, December 1, 2010; 2010(1): 387 - 396.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. Mahla, H. Metzler, U. S. Tantry, and P. A. Gurbel
Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery
Ann. Thorac. Surg., September 1, 2010; 90(3): 1040 - 1051.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
American Diabetes Association, American Heart Association, American College of Cardiology Foundation, M. Pignone, M. J. Alberts, J. A. Colwell, M. Cushman, S. E. Inzucchi, D. Mukherjee, R. S. Rosenson, et al.
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
J. Am. Coll. Cardiol., June 22, 2010; 55(25): 2878 - 2886.
[Full Text] [PDF]


Home page
CirculationHome page
M. Pignone, M. J. Alberts, J. A. Colwell, M. Cushman, S. E. Inzucchi, D. Mukherjee, R. S. Rosenson, C. D. Williams, P. W. Wilson, and M. S. Kirkman
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation
Circulation, June 22, 2010; 121(24): 2694 - 2701.
[Full Text] [PDF]


Home page
Diabetes CareHome page
M. Pignone, M. J. Alberts, J. A. Colwell, M. Cushman, S. E. Inzucchi, D. Mukherjee, R. S. Rosenson, C. D. Williams, P. W. Wilson, and M. S. Kirkman
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation
Diabetes Care, June 1, 2010; 33(6): 1395 - 1402.
[Full Text] [PDF]


Home page
BloodHome page
A. Dragani, S. Pascale, A. Recchiuti, D. Mattoscio, S. Lattanzio, G. Petrucci, L. Mucci, E. Ferrante, A. Habib, F. O. Ranelletti, et al.
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
Blood, February 4, 2010; 115(5): 1054 - 1061.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2010
Diabetes Care, January 1, 2010; 33(Supplement_1): S11 - S61.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. C. Becker, J. Scheiman, H. L. Dauerman, F. Spencer, S. Rao, M. Sabatine, D. A. Johnson, F. Chan, N. S. Abraham, E. M.M. Quigley, et al.
Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures
J. Am. Coll. Cardiol., December 8, 2009; 54(24): 2261 - 2276.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. I. Lev
Aspirin Resistance: Transient Laboratory Finding or Important Clinical Entity?
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 678 - 680.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement